These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1563 related articles for article (PubMed ID: 11007934)
1. New cytotoxic agents for the treatment of metastatic malignant melanoma: temozolomide and related alkylating agents in combination with guanine analogues to abrogate drug resistance. Spiro T; Liu L; Gerson S Forum (Genova); 2000; 10(3):274-85. PubMed ID: 11007934 [TBL] [Abstract][Full Text] [Related]
2. Mismatch repair mutations override alkyltransferase in conferring resistance to temozolomide but not to 1,3-bis(2-chloroethyl)nitrosourea. Liu L; Markowitz S; Gerson SL Cancer Res; 1996 Dec; 56(23):5375-9. PubMed ID: 8968088 [TBL] [Abstract][Full Text] [Related]
3. Temozolomide: the effect of once- and twice-a-day dosing on tumor tissue levels of the DNA repair protein O(6)-alkylguanine-DNA-alkyltransferase. Spiro TP; Liu L; Majka S; Haaga J; Willson JK; Gerson SL Clin Cancer Res; 2001 Aug; 7(8):2309-17. PubMed ID: 11489806 [TBL] [Abstract][Full Text] [Related]
4. Thresholds of O6-alkylguanine-DNA alkyltransferase which confer significant resistance of human glial tumor xenografts to treatment with 1,3-bis(2-chloroethyl)-1-nitrosourea or temozolomide. Kokkinakis DM; Bocangel DB; Schold SC; Moschel RC; Pegg AE Clin Cancer Res; 2001 Feb; 7(2):421-8. PubMed ID: 11234899 [TBL] [Abstract][Full Text] [Related]
5. Methyl DNA adducts, DNA repair, and hypoxanthine-guanine phosphoribosyl transferase mutations in peripheral white blood cells from patients with malignant melanoma treated with dacarbazine and hydroxyurea. Philip PA; Souliotis VL; Harris AL; Salisbury A; Tates AD; Mitchell K; van Delft JH; Ganesan TS; Kyrtopoulos SA Clin Cancer Res; 1996 Feb; 2(2):303-10. PubMed ID: 9816173 [TBL] [Abstract][Full Text] [Related]
6. Inactivation of O6-alkylguanine DNA alkyltransferase as a means to enhance chemotherapy. Rabik CA; Njoku MC; Dolan ME Cancer Treat Rev; 2006 Jun; 32(4):261-76. PubMed ID: 16698182 [TBL] [Abstract][Full Text] [Related]
7. Effect of O6-benzylguanine on alkylating agent-induced toxicity and mutagenicity. In Chinese hamster ovary cells expressing wild-type and mutant O6-alkylguanine-DNA alkyltransferases. Cai Y; Wu MH; Xu-Welliver M; Pegg AE; Ludeman SM; Dolan ME Cancer Res; 2000 Oct; 60(19):5464-9. PubMed ID: 11034089 [TBL] [Abstract][Full Text] [Related]
8. Chemotherapy-induced O(6)-benzylguanine-resistant alkyltransferase mutations in mismatch-deficient colon cancer. Liu L; Schwartz S; Davis BM; Gerson SL Cancer Res; 2002 Jun; 62(11):3070-6. PubMed ID: 12036916 [TBL] [Abstract][Full Text] [Related]
9. O6-benzylguanine: a clinical trial establishing the biochemical modulatory dose in tumor tissue for alkyltransferase-directed DNA repair. Spiro TP; Gerson SL; Liu L; Majka S; Haaga J; Hoppel CL; Ingalls ST; Pluda JM; Willson JK Cancer Res; 1999 May; 59(10):2402-10. PubMed ID: 10344750 [TBL] [Abstract][Full Text] [Related]
10. Sensitization of pancreatic tumor xenografts to carmustine and temozolomide by inactivation of their O6-Methylguanine-DNA methyltransferase with O6-benzylguanine or O6-benzyl-2'-deoxyguanosine. Kokkinakis DM; Ahmed MM; Chendil D; Moschel RC; Pegg AE Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3801-7. PubMed ID: 14506174 [TBL] [Abstract][Full Text] [Related]
11. 3-aminobenzamide and/or O6-benzylguanine evaluated as an adjuvant to temozolomide or BCNU treatment in cell lines of variable mismatch repair status and O6-alkylguanine-DNA alkyltransferase activity. Wedge SR; Porteous JK; Newlands ES Br J Cancer; 1996 Oct; 74(7):1030-6. PubMed ID: 8855970 [TBL] [Abstract][Full Text] [Related]
12. Effect of single and multiple administration of an O6-benzylguanine/temozolomide combination: an evaluation in a human melanoma xenograft model. Wedge SR; Porteous JK; Newlands ES Cancer Chemother Pharmacol; 1997; 40(3):266-72. PubMed ID: 9219512 [TBL] [Abstract][Full Text] [Related]
13. Potentiation of temozolomide and BCNU cytotoxicity by O(6)-benzylguanine: a comparative study in vitro. Wedge SR; Porteus JK; May BL; Newlands ES Br J Cancer; 1996 Feb; 73(4):482-90. PubMed ID: 8595163 [TBL] [Abstract][Full Text] [Related]
15. Protection of CHO cells by mutant forms of O6-alkylguanine-DNA alkyltransferase from killing by 1,3-bis-(2-chloroethyl)-1-nitrosourea (BCNU) plus O6-benzylguanine or O6-benzyl-8-oxoguanine. Loktionova NA; Xu-Welliver M; Crone TM; Kanugula S; Pegg AE Biochem Pharmacol; 1999 Jul; 58(2):237-44. PubMed ID: 10423163 [TBL] [Abstract][Full Text] [Related]
16. Inhibition of DNA repair for sensitizing resistant glioma cells to temozolomide. Kanzawa T; Bedwell J; Kondo Y; Kondo S; Germano IM J Neurosurg; 2003 Dec; 99(6):1047-52. PubMed ID: 14705733 [TBL] [Abstract][Full Text] [Related]
17. Clinical relevance of MGMT in the treatment of cancer. Gerson SL J Clin Oncol; 2002 May; 20(9):2388-99. PubMed ID: 11981013 [TBL] [Abstract][Full Text] [Related]
19. Phase II trial of the O6-alkylguanine DNA alkyltransferase inhibitor O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea in advanced melanoma. Gajewski TF; Sosman J; Gerson SL; Liu L; Dolan E; Lin S; Vokes EE Clin Cancer Res; 2005 Nov; 11(21):7861-5. PubMed ID: 16278409 [TBL] [Abstract][Full Text] [Related]
20. O6-(4-bromothenyl)guanine (PaTrin-2), a novel inhibitor of O6-alkylguanine DNA alkyl-transferase, increases the inhibitory activity of temozolomide against human acute leukaemia cells in vitro. Turriziani M; Caporaso P; Bonmassar L; Buccisano F; Amadori S; Venditti A; Cantonetti M; D'Atri S; Bonmassar E Pharmacol Res; 2006 Apr; 53(4):317-23. PubMed ID: 16412662 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]